274 related articles for article (PubMed ID: 19711426)
1. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
2. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
Fransvea E; Mazzocca A; Antonaci S; Giannelli G
Hepatology; 2009 Mar; 49(3):839-50. PubMed ID: 19115199
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
[TBL] [Abstract][Full Text] [Related]
4. Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
Wang Y; Wu J; Lin B; Li X; Zhang H; Ding H; Chen X; Lan L; Luo H
Toxicology; 2014 Dec; 326():9-17. PubMed ID: 25268046
[TBL] [Abstract][Full Text] [Related]
5. Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
Fransvea E; Mazzocca A; Santamato A; Azzariti A; Antonaci S; Giannelli G
Cancer Chemother Pharmacol; 2011 Jul; 68(1):79-86. PubMed ID: 20844878
[TBL] [Abstract][Full Text] [Related]
6. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
7. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
8. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Jiang F; Wang X; Liu Q; Shen J; Li Z; Li Y; Zhang J
Toxicol Lett; 2014 Nov; 231(1):55-61. PubMed ID: 25196641
[TBL] [Abstract][Full Text] [Related]
10. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
11. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
14. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
15. Involvement of signaling of VEGF and TGF-beta in differentiation of sinusoidal endothelial cells during culture of fetal rat liver cells.
Yoshida M; Nishikawa Y; Omori Y; Yoshioka T; Tokairin T; McCourt P; Enomoto K
Cell Tissue Res; 2007 Aug; 329(2):273-82. PubMed ID: 17450384
[TBL] [Abstract][Full Text] [Related]
16. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Fransvea E; Angelotti U; Antonaci S; Giannelli G
Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
[TBL] [Abstract][Full Text] [Related]
17. Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma.
Yang J; Lu Y; Lin YY; Zheng ZY; Fang JH; He S; Zhuang SM
Cancer Lett; 2016 Dec; 383(1):18-27. PubMed ID: 27693460
[TBL] [Abstract][Full Text] [Related]
18. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
20. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
